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Abstract: Dyslipidemia is a major vascular risk factor. Interestingly, several agents used for the prevention and treatment 
of vascular diseases have an adverse effect on the lipid profile. In addition, agents belonging to the same class (e.g. beta 
blockers) can have significantly different actions on lipid levels. We summarize the effects of drugs used for the preven-
tion and treatment of vascular diseases on the lipid profile. These effects should be considered when selecting a specific 
agent, particularly in high-risk patients. 
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INTRODUCTION 
  Elevated levels of low density lipoprotein cholesterol 
(LDL-C) are a major vascular risk factor [1]. Low levels of 
high density lipoprotein cholesterol (HDL-C) are also asso-
ciated with higher vascular morbidity and mortality [1-3]. 
The relationship between triglyceride (TG) levels and vascu-
lar events is more controversial but elevated TG levels also 
appear to be associated with increased vascular risk [4]. In-
terestingly, several agents that are used for the prevention 
and treatment of vascular diseases have an adverse effect on 
the lipid profile (Table 1). The aim of the present review is 
to summarize the effects of these drugs on lipids. 
SEARCH METHODS 
  A literature search (using PubMed) was performed using the 
following key words: “diuretics”, “beta blockers”, “calcium 
channel blockers”, “angiotensin converting enzyme inhibitors”, 
“angiotensin receptor blockers”, “alpha blockers”, “moxonidine”, 
“minoxidil”, “rosiglitazone”, “pioglitazone”, “metformin”, 
“sulphonylureas”, “insulin”, “acarbose”, “repaglinide”, “nateg-
linide”, “sitagliptin”, “vildagliptin”, “exenatide”, “pramlintide”, 
“orlistat”, “sibutramine”, “rimonabant”, “bile acid seques-
trants”, “fibrates”, “omega 3 fatty acids”, “LDL-C”, “HDL-C” 
and “triglycerides” up to 15 June 2009. The authors also   
manually reviewed the references of retrieved articles for any 
pertinent material. 
ANTIHYPERTENSIVE AGENTS 
  Non-selective beta blockers (e.g. propranol) increase TG 
levels and lower HDL-C levels without affecting LDL-C   
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levels [5, 6]. In contrast, beta1-selective blockers (e.g. at-
enolol and metoprolol) do not appear to have an adverse ef-
fect on the lipid profile [5, 7-10] and in some studies in-
creased HDL-C levels and lowered total cholesterol (TC) 
and TG levels [11]. However, atenolol increased TG levels 
in other studies [12, 13]. Both non-selective and beta1-
selective blockers may exacerbate preexisting hypertriglyc-
eridemia and cases of pancreatitis have been reported in pa-
tients treated with these agents [14, 15]. Beta1-selective 
blockers with intrinsic sympathomimetic activity (celiprolol, 
acebutolol and nebivolol) lowered LDL-C and TG levels and 
also increased HDL-C levels [5, 6]. Atenolol lowered HDL-
C levels and increased LDL-C and TG levels compared with 
celiprolol [16]. Nebivolol, a beta1-selective blocker which 
also stimulates nitric oxide release, does not appear to 
change lipid parameters significantly [8, 13]. However, a fall 
in HDL-C levels during nebivolol treatment was reported in 
another study [17]. Carvedilol, a non-selective beta blocker 
with alpha1 selective blocking activity, appears to have more 
beneficial effects on the lipid profile than beta1-selective 
blockers [11, 18, 19]. Carvedilol did not change TC levels 
but lowered TG levels and increased HDL-C levels more 
than atenolol [11]. In another study, atenolol decreased 
HDL-C levels more than carvedilol [18]. Carvedilol also 
lowered TC levels more than metoprolol [19]. In addition, 
metoprolol increased TG levels whereas carvedilol had no 
significant effect [19]. Interestingly, several polymorphisms 
of the beta2 and beta3 adrenoreceptor genes appear to be 
associated with increased risk for experiencing an increase in 
LDL-C and TG levels during treatment with beta blockers 
[20, 21]. 
  Hydrochlorothiazide at a dose of 6.25-12.5 mg/day does 
not appear to adversely affect the lipid profile [22]. Hydro-
chlorothiazide 25 mg/day did not change TC or HDL-C lev-
els but increased TG levels [12, 23]. A number of meta-
analyses showed that hydrochlorothiazide at a dose > 25 
mg/day increases TC and TG levels more than lower doses 86    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Tziomalos et al. 
[6, 24]. In addition, thiazide diuretics lowered HDL-C levels 
only in diabetic patients [6]. Interestingly, the increase in 
LDL-C and TG levels with thiazide diuretics appears to be 
more pronounced in men [6]. In addition, the rise in LDL-C 
levels appears to be greater in patients with higher baseline 
LDL-C levels [6]. Chlorthalidone increased LDL-C levels 
more than other thiazide diuretics [6]. The non-thiazide diu-
retic indapamide at a dose of 2.5 mg/day or at 1.5 mg/day in 
a sustained release form reduced blood pressure to an extent 
similar or greater than hydrochlorothiazide 25 mg/day [23, 
25]. Indapamide in these doses did not change TC, TG or 
HDL-C levels [23, 26]. However, in a meta-analysis inda-
pamide did not change TG levels but increased LDL-C lev-
els [6]. In comparative studies, indapamide 2.5 mg/day and 
hydrochlorothiazide 12.5 mg/day had a similar effect on 
lipid profile [27]. However, indapamide 2.5 mg/day in-
creased TG levels more than hydrochlorothiazide 25 mg/day 
[23]. 
  Calcium channel blockers appear to have neutral effects 
on the lipid profile [6, 28-31]. An increase in HDL-C levels 
was also reported in some studies [12, 32]. 
  Angiotensin converting enzyme inhibitors increased 
HDL-C levels and lowered TC and TG levels in some re-
ports [12, 30, 33]. In others, they did not affect the lipid pro-
file [7, 34] or lowered only LDL-C [35] or TG levels [6]. 
Angiotensin II receptor blockers increased HDL-C levels 
and lowered LDL-C and TG levels [28, 36-39]. In other 
studies they did not affect the lipid profile [35] or lowered 
only LDL-C levels [40].  
  Some large randomized controlled trials compared the 
effects of different classes of antihypertensive agents on the 
lipid profile. In the Losartan Intervention For Endpoint re-
duction in hypertension (LIFE) study, HDL-C levels de-
creased less with losartan-based treatment than with at-
enolol-based treatment [41]. In the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT), TC levels decreased more with amlodip-
ine- and lisinopril-based treatment than with chlorthalidone-
based treatment [42]. However, it is difficult to compare the 
effects of antihypertensive agents on lipids in randomized 
controlled trials since most patients in these studies are 
treated with multiple classes of antihypertensive agents. 
  Doxazosin, an alpha1-blocker, increased HDL-C levels 
and lowered LDL-C and TG levels [6, 33, 43]. Other alpha 
blockers have similar beneficial effects on the lipid profile 
[6]. The less frequently used antihypertensive agents 
moxonidine and minoxidil appear to lower LDL-C levels 
without affecting TG or HDL-C levels [44, 45]. 
ANTIDIABETIC AGENTS 
  Both rosiglitazone and pioglitazone increased LDL-C 
levels [46, 47]. However, it appears that pioglitazone lowers 
small dense LDL particles (which are potentially more 
atherogenic) whereas rosiglitazone has a smaller or no effect 
on LDL size [48-50]. In addition, rosiglitazone increased TG 
levels whereas pioglitazone decreased TG levels [46]. Both 
these thiazolidinediones increased HDL-C levels [46, 51]. In 
comparative studies, pioglitazone induced a greater reduc-
tion in TG levels, a larger increase in HDL-C levels, a 
smaller increase in TC and LDL-C levels as well as a greater 
shift towards larger, more buoyant LDL particles [48-50]. 
Other antidiabetic agents appear to have neutral or beneficial 
effects on the lipid profile. Metformin decreased TG and 
LDL-C levels and did not affect HDL-C levels [46]. Sul-
phonylureas, acarbose and glinides (repaglinide and nateg-
Table 1.  Adverse Lipid Effects of Agents Used for the Prevention and Treatment of Vascular Diseases 
Agent  Adverse Effect on The Lipid Profile  Reference 
Non-selective beta blockers   TG levels 
 HDL-C levels 
[5, 6, 14, 15] 
Beta1-selective blockers   TG levels (no effect or  in other studies)  [5, 7-15] 
Nebivolol   HDL-C levels (no effect in other studies)  [8, 13, 15] 
Hydrochlorothiazide ( 25 mg/day)   TG levels 
 TC levels 
[6, 22] 
Chlorthalidone   LDL-C levels  [6] 
Indapamide   LDL-C levels (no effect in other studies)  [6, 21, 24] 
Pioglitazone   LDL-C levels  [46, 47] 
Rosiglitazone   LDL-C levels 
 TG levels 
[46, 47] 
Orlistat   HDL-C levels  [56] 
Bile-acid sequestrants   TG levels  [1, 64-66] 
Fibrates   LDL-C levels (in patients with hypertriglyceridemia)  [1, 67] 
Omega-3 fatty acids   LDL-C levels (in patients with severe hypertriglyceridemia)  [68-70] 
TG = triglyceride; HDL-C = high density lipoprotein cholesterol; TC = total cholesterol; LDL-C = low density lipoprotein cholesterol. Dyslipidemia Induced by Vascular Drugs  The Open Cardiovascular Medicine Journal, 2011, Volume 5    87 
linide) decreased TG levels and did not affect LDL-C or 
HDL-C levels [46]. The “newer” oral antidiabetic drugs sita-
gliptin and vildagliptin (which inhibit dipeptidyl peptidase 
IV) appear to have a neutral effect on the lipid profile [52]. 
Preliminary data suggest that vildagliptin improves post-
prandial lipemia [53]. Insulin appears to reduce TG and in-
crease HDL-C levels, particularly in patients with poor gly-
cemic control [54]. “Newer” antidiabetic agents adminis-
tered by subcutaneous injection include exenatide (a gluca-
gon-like peptide 1 agonist) and pramlintide (an amylin ana-
logue) [54]. Neither exenatide nor pramlintide appear to alter 
the lipid profile significantly [52, 55]. 
ANTIOBESITY AGENTS 
  Orlistat not only reduces body weight but also lowers 
LDL-C levels [56]. However, a small but significant de-
crease in HDL-C levels was reported during orlistat treat-
ment [56]. Orlistat does not appear to alter TG levels signifi-
cantly [56]. Sibutramine, another agent approved for the 
management of obesity, decreases TG levels and increases 
HDL-C concentration [56]. Sibutramine does not signifi-
cantly affect LDL-C levels [56]. Rimonabant, an antiobesity 
agent that was withdrawn for safety reasons, increased HDL-
C levels and reduced TG levels [57-63]. 
LIPID PROFILE-MODIFYING AGENTS 
  Bile-acid sequestrants (resins) decrease LDL-C levels but 
also increase TG levels [1]. Colesevelam, a newer resin 
which appears to be better tolerated than older members of 
this class, also increased TG levels [64-66]. Accordingly, 
resin monotherapy is contraindicated in patients with TG 
levels > 400 mg/dl (4.5 mmol/l) and should be avoided when 
TG levels are > 200 mg/dl (2.2 mmol/l) [1]. 
  In patients with hypercholesterolemia, fibrates lower 
LDL-C levels by 10-20% [1, 67]. However, an increase in 
LDL-C levels might be observed when fibrates are given to 
patients with hypertriglyceridaemia [1, 67]. This appears to 
be due to an increase in very low density lipoprotein (VLDL) 
lipolysis by lipoprotein lipase [67]. 
  Omega-3 fatty acids lower TG levels but increase LDL-C 
levels, particularly in patients with severe hypertriglyc-
eridemia [68-70]. This increase in LDL-C levels appears to 
be due to a shift to larger, more buoyant and (potentially) 
less atherogenic LDL particles [68, 71, 72]. Interestingly, in 
patients with hypertriglyceridemia who were treated with 
statins, adding omega-3 fatty acids did not affect LDL-C 
levels [73]. In addition, omega-3 fatty acids lowered LDL-C 
levels in patients with normal TG levels [68, 70]. 
CONCLUSIONS 
  Several drugs used for the prevention and treatment of 
vascular diseases appear to have an adverse effect on the 
lipid profile. Moreover, agents belonging to the same class 
(e.g. beta-blockers) can have significantly different actions 
on lipid levels. These effects might have to be considered 
when selecting a specific agent, particularly in high-risk pa-
tients. However, it is unclear whether the adverse lipid ef-
fects of these agents reduce their protective effect against 
vascular events. In addition, the effect on lipids is a surrogate 
endpoint. Therefore, only large randomized clinical trials 
with vascular endpoints should guide our therapeutic deci-
sions. 
LIST OF ABBREVIATIONS 
HDL-C  =  High density lipoprotein cholesterol 
LDL-C  =  Low density lipoprotein cholesterol 
LIFE  =  Losartan Intervention For Endpoint reduction 
in hypertension 
TC =  Total  cholesterol 
TG =  Triglyceride 
VLDL  =  Very low density lipoprotein 
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